Impact of 131I SPECT/spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation
Overview
Affiliations
Unlabelled: The purpose of this study was to determine the diagnostic value of 131I SPECT/spiral CT (SPECT/CT) on nodal staging of patients with thyroid carcinoma at the first ablative radioiodine therapy.
Methods: Fifty-seven patients were studied using SPECT/CT 3-4 d after receiving 3.96+/-0.5 GBq of 131I for radioablation of thyroid remnants after a thyroidectomy for differentiated thyroid carcinoma. In addition to planar whole-body scintigraphy, SPECT/CT of the neck was performed using a hybrid camera combining a double-head SPECT camera with either a 2-slice (n=23) or a 6-slice (n=34) spiral CT scanner. The planar scans and the SPECT/CT images were evaluated for cervical tracer uptake independently of each other and of the clinical findings.
Results: SPECT/CT led to a revision of the original diagnosis in 28 of 143 cervical foci of radioiodine uptake seen on planar imaging. In particular, SPECT/CT reclassified as benign 6 of 11 lesions considered to be lymph node metastases and 11 of 15 lesions considered to be indeterminate. Furthermore, SPECT/CT allowed the identification of 11 lymph node metastases classified as thyroid remnant or as indeterminate on planar imaging. Based on this revision, SPECT/CT yielded a gain in information on nodal stage in 20 of the 57 patients studied (35%, P<0.03). SPECT/CT altered nodal stage from N0 to N1 in 2 of 20 patients and from indeterminate (Nx) to N1 in 6 of 30 patients. The result was a change in risk stratification conforming to the classification proposed by the International Union Against Cancer in 14 patients (25%).
Conclusion: SPECT/CT determines lymph node involvement at radioablation performed for thyroid cancer more accurately than does planar imaging. SPECT/CT may alter management in roughly one quarter of patients with thyroid carcinoma by upstaging or downstaging their disease.
Pre-Treatment and Post-Treatment I-131 Imaging in Differentiated Thyroid Carcinoma.
Mihailovic J J Clin Med. 2024; 13(7).
PMID: 38610749 PMC: 11012677. DOI: 10.3390/jcm13071984.
Jia X, Wang Y, Yang L, Fan K, Tao R, Liu H Diagnostics (Basel). 2022; 12(5).
PMID: 35626409 PMC: 9140362. DOI: 10.3390/diagnostics12051254.
Ahmadi S, Coleman A, Silva de Morais N, Landa I, Pappa T, Kang A Endocr Connect. 2022; 11(5).
PMID: 35521806 PMC: 9175585. DOI: 10.1530/EC-21-0371.
Evaluation of Diagnostic Value of SPECT/CT Imaging in Post-radioiodine Therapy in Thyroid Cancer.
Al Hatmi A, Jain A, Mittal A, Hussain S Sultan Qaboos Univ Med J. 2022; 22(1):74-81.
PMID: 35299812 PMC: 8904107. DOI: 10.18295/squmj.4.2021.054.
Guo Y, Xu J, Li X, Zheng L, Pan W, Qiu M Front Oncol. 2021; 11:762643.
PMID: 34778083 PMC: 8581297. DOI: 10.3389/fonc.2021.762643.